Revenue grew 3.75% to ¥5.91 billion, but net profit fell 7.54% to ¥1.06 billion due to higher R&D and operating costs. The company maintained strong cash flow, expanded its CNS drug pipeline, and proposed a ¥4.00 per 10 shares dividend.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.